Endosense, developer of catheter ablation technology for the treatment of cardiac arrhythmias, has announced that it has secured an additional US$4.3 million in series C financing from a new strategic industry partner. This second successful closing brings the total in series C funds raised to US$44.6 million.
“The receipt of the additional series C funds represents a tremendous vote of confidence in our contact-force sensing technology and its power to transform the standard of care in the catheter ablation treatment of cardiac arrhythmias,” said Jan Keltjens, president, chief executive officer and chairman of Endosense. “The added finances will further support the development of our exciting pipeline, the roll-out of our TactiCath Quartz contact-force sensing ablation catheter in Europe with a new direct sales force, and our programme to get access to the US market. All of these initiatives are solidifying our leadership position in the field.”
In November 2012, the company disclosed the successful closing of US$40.3 million in series C financing, which was led by new investor NGN Capital and included large participation from all existing investors, as well as multiple employees.
The TactiCath received the CE mark in May 2009. In the United States it is an investigational device. Limited by Federal (or United States) law to investigational use.